After their earnings release Thursday morning, IBD 50 member Vertex Pharmaceuticals fell hard in heavier volume. No clear indication why it fell, but it has gapped up today on the open.
For a full breakdown of the stock, see Allison Gatlin's report, Vertex Shrugs Off Regular-Session Malaise As International Sales Drive Quarterly Beat.
As always, it's risky to buy any stock just before it reports. You can minimize your risk by waiting to see the actual numbers and the market's reaction. Using an options strategy during earnings season is another way to put yourself in a position to profit, while minimizing the potential downside.
See How IBD Helps You Make More Money In Stocks
The company posted 14% earnings growth in the current quarterly report. Revenue gains came in at 18%.
Analysts expected earnings-per-share growth of 1% for the quarter, and 41% growth for the full year.
Vertex Pharmaceuticals still holds a 99 Composite Rating and earns the No. 1 rank among its peers in the Medical-Biomed/Biotech industry group. Genmab also among the group's highest-rated stocks.
Note: Dates for earnings reports are subject to change. Check the company's website for any updates.
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
